PSTV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases...

Stats
Today's Volume	17 794.00
Average Volume	697 977
Market Cap	7.55M
EPS	$0 ( 2023-10-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.280
ATR14	$0.0270 (1.62%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-16	Lenk Robert P	Buy	1 000	Common Stock
2023-11-15	Lenk Robert P	Buy	1 000	Common Stock
2023-11-13	Lenk Robert P	Buy	4 000	Common Stock
2023-11-10	Lenk Robert P	Buy	2 000	Common Stock
2023-11-09	Lenk Robert P	Buy	4 199	Common Stock

INSIDER POWER
99.68
Last 94 transactions
Buy: 2 132 872 \| Sell: 1 186 941

Correlation (AI algo v.1.1b): Undervalued: 12.50% $1.879 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.10 (neutral)

Short: 0.64 (weak)

Signal:(45.48) Neutral

Plus Therapeutics Inc Correlation

10 Most Positive Correlations
VTSI	0.878
EDIT	0.833
ALVR	0.822
MDVL	0.813
LSBK	0.811
SPRO	0.805

10 Most Negative Correlations
BNIXU	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Plus Therapeutics Inc Correlation - Currency/Commodity

-0.26
( neutral )

0.27
( neutral )

0.00
( neutral )

0.04
( neutral )

0.00
( neutral )

-0.77
( moderate negative )

Plus Therapeutics Inc Financials

Annual	2022
Revenue:	$224 000
Gross Profit:	$224 000 (100.00 %)
EPS:	$-11.91

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.000

Q2	2023
Revenue:	$1.85M
Gross Profit:	$1.85M (100.00 %)
EPS:	$-0.590

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.07

Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.